Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TVI Colon 1

Next Previous
X
Search
Drug Profile

TVI Colon 1

Alternative Names: TVI-Colon-1

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TVAX Biomedical
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Colorectal cancer

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (IV, Infusion)
  • 14 Dec 2020 Preclinical trial is still ongoing in USA for Colorectal cancer (TVAX Biomedical website, December 2020)
  • 14 Dec 2020 TVAX Biomedical has patent protection for its immunotherapy platform in the USA, Canada and in several European countries before December 2020 (TVAX Biomedical website, December 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top